Document Detail

Replacement of carvedilol for propranolol in patients with heart failure.
MedLine Citation:
PMID:  20563524     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Large clinical trials using the betablockers carvedilol, metoprolol, bisoprolol and nebivolol have demonstrated improvement of survival and symptoms in patients with heart failure. Despite the lack of scientific evidence, it is plausible that their beneficial effects are extensible to other betablockers.
OBJECTIVE: To evaluate the impact of the replacement of carvedilol for propranolol on left ventricular function, functional capacity, quality of life, pressure levels, and cardiac autonomic control in patients with heart failure.
METHODS: Twenty nine patients receiving optimized drug therapy including maximum tolerated doses of carvedilol were divided into two groups: replacement of carvedilol for propranolol (n = 15) and continued carvedilol (n = 14). At baseline and 6 months later, clinical and laboratorial assessments were carried out with radionuclide ventriculography, echocardiography, Minnesota questionnaire, walk test, APBM and Holter monitoring.
RESULTS: The clinical and demographic characteristics were similar in the two groups at baseline. Individualized propranolol dose adjustment ensured a similar degree of beta-blockade, as assessed by resting heart rate and chronotropic reserve. The mean propranolol dose used was 109 +/- 43 mg/day. Only one patient presented with intolerance to propranolol, thus carvedilol was reintroduced. One death was recorded in group propranolol. Ejection fraction significantly increased in the propranolol group. No significant change was observed in the other cardiovascular variables after betablocker replacement.
CONCLUSION: Our results indicate that replacement of carvedilol for propranolol in patients with heart failure is not associated with deterioration of the ejection fraction, functional capacity, quality of life, and other cardiovascular variables related to autonomic and blood pressure control., PP.0-0).
Fabiana Marques; Renato Barroso Pereira de Castro; Fernando Nobre; Antonio Osvaldo Pintya; Lourenço Gallo Jr; Benedito Carlos Maciel; Marcus Vinícius Simões
Related Documents :
3401644 - Comparison of the haemodynamic effects of the selective bradycardic agent ul-fs 49, wit...
449144 - Prophylactic lidocaine in suspected acute myocardial infarction.
11450034 - Clinical use of lidocaine for control of stroke oedema in the posterior cranial fossa a...
9649354 - Tachycardia alone fails to change the myocardial pharmacokinetics and dynamics of lidoc...
2886234 - Effects of chronic progressive myocardial hypertrophy on indexes of cardiac autonomic i...
12628714 - Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejectio...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2010-06-11
Journal Detail:
Title:  Arquivos brasileiros de cardiologia     Volume:  95     ISSN:  1678-4170     ISO Abbreviation:  Arq. Bras. Cardiol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-08-09     Completed Date:  2011-09-29     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0421031     Medline TA:  Arq Bras Cardiol     Country:  Brazil    
Other Details:
Languages:  eng     Pagination:  107-14     Citation Subset:  IM    
Hospital das Clínicas, Faculdade de Medicina de Ribeirão, USP, Ribeirão Preto, SP, Brasil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use*
Carbazoles / therapeutic use*
Drug Substitution*
Follow-Up Studies
Heart Failure / drug therapy*,  ultrasonography
Middle Aged
Propanolamines / therapeutic use*
Propranolol / therapeutic use*
Prospective Studies
Treatment Outcome
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 0K47UL67F2/carvedilol; 525-66-6/Propranolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antibodies against oxLDL and acute coronary syndrome.
Next Document:  Comparative study of the pro-atherosclerotic profile of students of medicine and physical education.